Slide 1: Glenmark Pharmaceuticals Ltd. Investor Presentation: Q4 & FY23
Presentation Heading or Sub Heading Glenmark Pharmaceuticals Ltd. Investor Presentation: Q4 & FY23 19 May 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Glenmark Pharmaceuticals Ltd. The information, statements and analysis made in this presentation describing Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. These statements are based on current expec
Slide 3: Glenmark's vision has guided its journey over the last two decades
Glenmark’s vision has guided its journey over the last two decades Glenmark Group, today Leading Integrated Research-led Global Consolidated revenues in FY23: End-to-end R&D capabilities: API, Initiated NME research in 2002; Global diversified formulations ₹ 129,901 mn generic formulations (conventi
Slide 4: Strategic restructuring for sharper focus on our three businesses
Strategic restructuring for sharper focus on our three businesses Separate board Independent Global presence of directors management team & operations Primarily focused on building a global formulation business with branded, generics, and OTC segments in therapy areas of Dermatology, Respiratory and
Slide 5: Committed to Sustainability across all our operations globally
Committed to Sustainability across all our operations globally Environmental Social Governance Become carbon neutral by 2030* 16 global safety programs by 2023 Maintain an ethical business culture to Achieve water neutral operations by Aspire to impact 3 million lives by 2025 drive robust governance
Slide 6: Q4 FY23 Snapshot
Q4 FY23 Snapshot Revenues from Operations at Rs. 33,737 Mn with a growth of 11.7% YoY EBITDA of Rs. 6,050 Mn with EBITDA margin of 17.9% “We delivered yet another year of robust performance, despite the Consolidated Revenue of Rs. 33,737 Mn; growth of 11.7% YoY challenging global macro-economi
Slide 7: FY23 Snapshot
FY23 Snapshot Revenues from Operations at Rs. 129,901 Mn with a growth of 5.6% YoY EBITDA of Rs. 22,784 Mn with EBITDA margin of 17.5% Consolidated Revenue of Rs. 129,901 Mn; growth of 5.6% YoY Key regions driving growth across the year: Europe and ROW Strong recovery in the North America
Slide 8: Key Highlights in FY23
Key Highlights in FY23 Glenmark was ranked 2nd in Respiratory in India with 1.5x higher value growth compared to the overall Respiratory market1 Glenmark’s Europe business continued Glenmark’s ROW business recorded 20%+ strong growth momentum to record growth across all sub-regions revenue of USD 22
Slide 9: Consolidated Revenues from Operations - Q4 FY23
Consolidated Revenues from Operations - Q4 FY23 Fourth Quarter ended March 31 Third Quarter ended December 31 YoY Growth QoQ Growth Rs Mn FY 2022-23 FY 2021-22 FY 2022-23 (%) (%) India 8,284 8,847 -6.4% 10,745 -22.9% North America 8,507 7,378 15.3% 8,373 1.6% Europe 6,078 4,968 22.3% 4,932 23.2% Res
Slide 10: Consolidated Revenues from Operations - FY23
Consolidated Revenues from Operations - FY23 Twelve Months ended March 31 YoY Growth Rs Mn FY 2022-23 FY 2021-22 (%) India 40,298 40,855 -1.4% North America 31,041 30,366 2.2% Europe 18,094 15,218 18.9% Rest of the World1 23,777 21,672 9.7% API 14,582 12,709 14.7% Total 127,791 120,820 5.8% Other Re
Slide 11: Revenue Distribution by Key Geographies
Revenue Distribution by Key Geographies 2% 2% 10% 11% 33% 31% 18% 18% FY22 FY23 12% 14% 25% 24% India Europe API North America ROW Other Revenue 11
Slide 12: P&L Highlights
P&L Highlights Rs. Mn Q4 FY23 Q4 FY22 %YoY Q3 FY23 %QoQ FY23 FY22 %YoY Revenues from Operations 33,737 30,191 11.7% 34,639 -2.6% 129,901 123,049 5.6% EBITDA 6,050 4,634 30.5% 6,202 -2.5% 22,784 23,203 -1.8% EBITDA margin (%) 17.9% 15.3% 17.9% 17.5% 18.9% Other Income (exp) (402) 1,072 764 3,168 1,66
Slide 13: Balance Sheet Highlights
Balance Sheet Highlights Rs. Mn Mar-23 Mar-22 Trade Receivables 40,986 31,011 Inventory 29,778 24,998 Payables 23,919 22,887 Gross Debt 43,477 36,703 Net Debt 29,047 22,598 13
Slide 14: India
FY23 31% India YoY: -6.4% Revenue (INR Mn) QoQ: -22.9% Glenmark now ranked 2nd Continuous in the Respiratory outperformance 10,745 segment compared to industry 8,284 8,847 Key Highlights Decline in Q4 FY23 on account of impact of divestment of few non-core brands, impact of Q4 FY23 Q4 FY22 Q3 FY23
Slide 15: North America
FY23 North America 24% YoY: 15.3% Revenue (INR Mn) QoQ: 1.6% 8 ANDA filings in FY23; 8 ANDA approvals and 8 10-12 filings targeted in 8,507 8,373 launches in FY23 FY24 7,378 Key Highlights Notable approvals include: Sodium Phenylbutyrate Tablets USP, 500 mg; Nicardipine Hydrochloride Capsules; Cli
Slide 16: Europe
FY23 Europe 14% YoY: 22.3% Revenue (INR Mn) QoQ: 23.2% Filed four additional Revenue of USD 225+ Mn respiratory products for 6,078 in FY23 Europe in FY23 4,968 4,932 Key Highlights Q4 FY23 Q4 FY22 Q3 FY23 Continued strong growth of 20%+ across the region, contributed by both Western Europe and Cen
Slide 17: ROW (Asia, MEA, LATAM and RCIS regions)
FY23 ROW (Asia, MEA, LATAM and RCIS regions) 18% YoY: 25.1% Revenue (INR Mn) QoQ: 4.8% Strong contribution from 20%+ growth across the Respiratory and 6,856 sub-regions 6,541 Dermatology segments 5,479 Key Highlights RCIS Growth of 10.3% in value for Glenmark Russia; Ryaltris® continues to gain in
Slide 18: API business - Glenmark Life Sciences
11% FY23 API business - Glenmark Life Sciences YoY: 16.7% Revenue – External Sales (INR Mn) QoQ: 2.0% Consolidated sales CDMO revenue grew by (including captive sales) 30% YoY in Q4 FY23 3,831 growth of 21% YoY 3,756 3,283 Key Highlights Q4 FY23 Q4 FY22 Q3 FY23 Revenues from operations including c
Slide 19: Respiratory Strategy – Creating Global Scale
Respiratory Strategy – Creating Global Scale As of Q4 FY23, marketing applications for Ryaltris® have been submitted in more than 70 countries, the product has been commercialized in 27 markets Glenmark’s partner in the EU, Menarini, initiated commercial launch in Austria, Belgium, France, and S
Slide 20: Innovative R&D Pipeline
Innovative R&D Pipeline Currently being developed as an orally administered immunotherapeutic agent for patients with solid tumors; demonstrated substantial anti-tumor effects in pre-clinical studies when administered alone, which is further enhanced when administered in combination with currently
Slide 21: Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology
Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology Global footprint: the U.S. and Switzerland Fully Integrated Fully owned by Glenmark, with plans to expand the investor base in the future Biotech Accomplished management team with proven track
Slide 22: Ichnos is Advancing a Differentiated Pipeline with Potential First- and Best-in-Class Assets
Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets Ichnos Oncology Pipeline - First Wave Focuses on T-Cell Ichnos to Out-License Assets in Autoimmune (AI) Disease Engagers and Macrophage Modulators Molecule Molecule Potential Phase/Status Lead Indication Me
Slide 23: Key Objectives of Financial Year 2024
Key Objectives of Financial Year 2024 1 Consolidated revenue growth: 10-11% 2 Consolidated R&D investment: 8-8.5% of total sales 3 Consolidated EBITDA margin: 19-20%+ 4 Consolidated Capex: INR 6-7 Bn 5 Priority to enhance free cash generation for further debt reduction 6 Close at least 1 out-licensi
Slide 24: Thank You
Thank You https://glenmarkpharma.com/